12 completed. 12 Phase 3, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 12 | Completed 12 |
| Phase 2 | 5 | Completed 5 |
Follow Diabetes Type 2: new trials by email Literature Review of Diabetes Type 2 trials Research Report on Diabetes Type 2
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1) Retatrutide, Placebo - Diabetes Type 2 | Phase 3 | Completed | Eli Lilly and Company | 537 | 2024-04-10 | 2026-03-05 |
| A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes Tirzepatide, Placebo - Diabetes Type 2, Diabetes Mellitus | Phase 3 | Completed | Eli Lilly and Company | 257 | 2023-02-05 | 2025-08-08 |
| Lifestyle Interventions for Expectant Mothers (LIFE-Moms Phoenix) - Phoenix Enhanced standard care, Intensive lifestyle intervention - Obesity, Diet Therapy | Phase 3 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 123 | 2013-03-28 | 2026-10-08 |
| Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus Exenatide once weekly suspension, Sitagliptin, Placebo - Diabetes Type 2 | Phase 3 | Completed | AstraZeneca | 365 | 2013-02-01 | 2015-08-20 |
| Grain Exercise Trial - Whole Grain Versus no Grain With or Without Physiotherapy-promoted Exercise for Waist Loss Diet A, Diet B, Physiotherapy - Abdominal Obesity, Cardiovascular Diseases | Phase 2 / Phase 3 | Completed | Lund University | 105 | 2010-08-01 | 2017-06-20 |
| A Study of OPC-262 in Patients With Type 2 Diabetes OPC-262 2.5 mg, OPC-262 5 mg, Placebo - Diabetes Type 2 | Phase 2 / Phase 3 | Completed | Kyowa Kirin Co., Ltd. | 255 | 2009-09-01 | 2014-01-08 |
| Study on DMMET-01 Versus Metformin on Improvement of Metabolic Control in Naive Type 2 Diabetes Patients DMMET-01, Metformin Hydrochloride - Diabetes Type 2 | Phase 2 / Phase 3 | Completed | Laboratorios Silanes S.A. de C.V. | 20 | 2009-03-01 | 2010-05-18 |
| Acetyl-L-Carnitine in Type 2 Diabetes acetyl-L-carnitine/statin (simvastatin), placebo - Diabetes Type 2, Hypertension | Phase 3 | Completed | Mario Negri Institute for Pharmacological Research | 229 | 2008-04-01 | 2013-02-25 |
| Gait and Balance of Diabetes Type 2 Patients Physiotherapy - Diabetes Type 2 | Phase 2 / Phase 3 | Completed | University Hospital, Geneva | 71 | 2007-09-01 | 2010-01-14 |
| Efficacy of N-Acetylcysteine in Treatment of Overt Diabetic Nephropathy N-acetylcysteine - Diabetic Nephropathy, Chronic Kidney Disease | Phase 2 / Phase 3 | Completed | Shiraz University of Medical Sciences | 60 | 2007-01-01 | 2007-11-12 |
| Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up Technosphere® Insulin Inhalation Powder, 70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin) - Diabetes Type 2 | Phase 3 | Completed | Mannkind Corporation | 677 | 2006-02-01 | 2014-10-16 |
| Comparison Between Technosphere/Insulin Inhalation Powder Versus Rapid Acting Insulin in Subjects With Type 2 Diabetes Mellitus Technosphere Insulin - Diabetes Type 2 | Phase 3 | Completed | Mannkind Corporation | 2005-11-01 | 2009-10-14 |
Diabetes Mellitus, Type 2 (12) · Diabetes Mellitus (3) · Endocrine System Diseases (2) · Glucose Metabolism Disorders (2) · Hypertension (2) · Metabolic Diseases (2) · Cardiovascular Diseases (1) · Diabetic Nephropathies (1) · Glucose Intolerance (1) · Obesity (1) · Obesity, Abdominal (1) · Overweight (1) · Proteinuria (1) · Renal Insufficiency, Chronic (1) · Stroke (1)
Nutritional and Metabolic Diseases (12) · Endocrine System Diseases (10) · Glucose Metabolism Disorders (10) · Metabolic Diseases (10) · Diabetes Mellitus (9) · Pathological Conditions, Signs and Symptoms (3) · Signs and Symptoms (3) · Body Weight (2) · Body Weight Changes (2) · Nutrition Disorders (2) · Overnutrition (2) · Vascular Diseases (2) · Brain Diseases (1) · Cardiovascular Diseases (1) · Central Nervous System Diseases (1)
Physical Therapy Modalities (2) · Acetylcarnitine (1) · Acetylcysteine (1) · Exercise (1) · Hydroxymethylglutaryl-CoA Reductase Inhibitors (1) · Insulin Aspart (1) · Metformin (1) · Simvastatin (1) · Sitagliptin Phosphate (1) · Tirzepatide (1) · Whole Grains (1) · retatrutide (1)
Eli Lilly and Company (2) · Mannkind Corporation (2) · AstraZeneca (1) · Kyowa Kirin Co., Ltd. (1) · Laboratorios Silanes S.A. de C.V. (1) · Lund University (1) · Mario Negri Institute for Pharmacological Research (1) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) · Shiraz University of Medical Sciences (1) · University Hospital, Geneva (1)
United States (4) · Mexico (3) · Russia (2) · Argentina (1) · Brazil (1) · Canada (1) · Chile (1) · China (1) · India (1) · Iran (1) · Italy (1) · Japan (1) · Poland (1) · Puerto Rico (1) · Spain (1)
Kaatsuhisa Saito (1) · Lara E Allet, MPtSc (1) · Mary A Hoskin, R.D. (1) · Peter Ohman (1) · Piero Ruggenenti, MD (1) · Robert Baughman, PhD (1) · Staffan Lindeberg, MD PhD (1)
PMID 18579384, PMID 19138520, PMID 19900232, PMID 19921145, PMID 20609970, PMID 21999640, PMID 26708836, PMID 28205322, PMID 30230252, PMID 32306296, PMID 33238176, PMID 38639002, PMID 40839263, PMID 41029405, PMID 41039470, PMID 41167231, PMID 42250575